<p>CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors</p>

Abstract

Purpose Pancreatic cancer is associated with a high mortality rate owing to insufficient approaches for early diagnosis and the invasive biological behavior of the cancer. CD26 is a membrane-anchored protein involved in multiple physiological and pathological processes. Here, we investigated correlations between CD26 expression and clinicopathological features in patients with pancreatic tumors. Methods We collected 170 tumor tissue specimens and 138 paired paratumoral tissues from patients with pancreatic tumors and evaluated CD26 expression using immunohistochemistry. Results CD26 was expressed in 79.4% of pancreatic tumors, which was significantly ( P < 0.001) higher than that in paratumoral pancreatic tissues (23.2%). High expression of CD26 was correlated with ABO blood type ( P = 0.035), malignancy degree ( P = 0.001), CA199 ( P = 0.01), and CA242 ( P = 0.027). In pancreatic malignancies, CD26 expression was observed in 80.7% (130/161) of cases. Lower CD26 expression was correlated with longer disease-free survival ( P = 0.048) and overall survival ( P = 0.024) and was an independent predictor of overall survival (hazard ratio [HR]: 1.713; P = 0.042). Similar results were observed in pancreatic ductal adenocarcinoma (PDAC) tissues, and CD26 expression level (HR: 2.117; P = 0.008) was an independent predictor of overall survival in patients with PDAC. CD26 expression was significantly increased in pancreatic tumors and gradually increased with increasing malignancy degree, suggesting that CD26 may be involved in the tumorigenic proliferation of pancreatic tumors. Conclusion Therefore, CD26 is a potential marker for early diagnosis and a promising therapeutic target in pancreatic tumors.

The Role of Serum CD26 in the Diagnosis of Gastric Cancer

“…20,21 Recently, over-expression of CD26 was founded in several cancers, including malignant mesothelioma, 22 thyroid cancer, 23 urothelial cancer, 24 and pancreatic cancer. 25 In contrast, under-expression of CD26 has also been reported in colorectal cancer (CRC). Cordero et al reported decreased serum CD26 levels in patients with CRC compared to healthy controls in early CRC.…”

CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology

“…On the other hand, an increased CD26 expression level has been associated with poor prognosis in pancreatic cancer patients [ 46 ] and other cancers [ 40 , 50 ]. DPP-4 expression in the primary tumor may regulate cancer behavior; however, the expression of DPP-4 in the primary tumor appears to be the heterogeneity patterns, depending on tumor type, stage, microenvironment, and host condition.…”

DPP4 Is a Potential Prognostic Marker of Thyroid Carcinoma and a Target for Immunotherapy

“…DPP4 is an oncogene or tumor suppressor gene in different tumors in humans. Overexpression of DPP4 is associated with poor survival in patients with squamous cell lung cancer [ 9 ], hepatocellular carcinoma [ 10 ], renal clear cell carcinoma [ 11 ], pancreatic carcinoma [ 12 ], and colorectal cancer [ 13 ]. However, DPP4 is a tumor suppressor in nonsmall cell lung cancer [ 14 ], ovarian cancer [ 15 ], endometrial cancer [ 16 ], and prostatic cancer [ 17 ].…”